[1] Gersowsky DB, Mohiuddin K, Deasey C, et al. A patient's journey with rare biphenotypic hepatocellular carcinoma and cholangiocarcinoma.Cureus,2020,12(8):e9838. [2] Holzner ML,Tabrizian P,Parvin-Nejad FP,et al.Resection of mixed hepatocellular-cholangiocarcinoma, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma. Liver Transpl,2020,26(7):888-898. [3] Choi SH, Jeon SK, Lee SS, et al. Radio-pathologic correlation of biphenotypic primary liver cancer (combined hepatocellular cholangiocarcinoma): changes in the 2019 WHO classification and impact on LI-RADS classification at liver MRI. Eur Radiol,2021,31(12):9479-9488. [4] Malone CD, Gibby W, Tsai R, et al. Outcomes of yttrium-90 radioembolization for unresectable combined biphenotypic hepatocellular-cholangiocarcinoma. J Vasc Interv Radiol,2020,31(5):701-709. [5] Zeng GX, Deng XS, Wang YL. Prognostic model of hepatocellular carcinoma based on cancer grade. World J Clin Cases,2023,11(27):6383-6397. [6] Deng YM, Han WT, Wang GY, et al. Grading clear cell renal cell carcinoma grade using diffusion relaxation correlated MR spectroscopic imaging. JMRI,2023,59(2):699-710. [7] Hwang SY, Danpanichkul P, Agopian V, et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment.Clin Mol Hepatol,2025,31(Suppl):S228-S254. [8] Elboraey M, Devcic Z, Montazeri SA, et al. Natural history of incidental enhancing nodules on cone-beam computed tomography during transarterial therapy of hepatocellular carcinoma. J Vasc Interv Radiol,2021,32(8):1186-1192. [9] Beaufrère A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: an update. J Hepatol,2021,74(5):1212-1224. [10] Bo S, Lijie Z, Dongqiao X, et al. The effect of alcohol consumption in unresectable hepatocellular carcinoma with transarterial chemoembolization.J Oncol,2022, 2022:7062105. [11] 陈启全,李晓婷,杨勋祎,等. 超声造影、剪切波弹性成像和增强CT检查诊断肝细胞癌价值分析.实用肝脏病杂志,2023,26(3):408-411. [12] 郑巧灵,冯昌银,连渊娥,等. 双表型肝细胞癌六例临床病理学分析. 中华病理学杂志,2020,49(12):1320-1322. [13] Wang Z, Zeng Y, Wang YP, et al. A bile acid-related prognostic signature in hepatocellular carcinoma. Sci Rep,2022,12(1):22355-22355. [14] Lin MM, Kang FE, Lin GM, et al. Identification and functional characterization of potential oncofetal targets in human hepatocellular carcinoma. STAR Protocols,2022,3(4):218-222. [15] Jin KY, Han CC, Chen CS, et al. Liver collision tumor of primary hepatocellular carcinoma and neuroendocrine carcinoma: A rare case report. World J Clin Cases,2022,10(35):13129-13137. [16] Young S R,Soo P S. A rare cause of obstructive jaundice in a patient with hepatocellular carcinoma. Dig Liver Dis,2022,54(12):1721-1722. [17] 卫美蓉,王笑峰,罗兵. lncRNA MALAT1及GAS5的多态性与肝细胞癌遗传易感性的关联.中华疾病控制杂志,2023,27(5):587-592. [18] Yingqi F, Wei W, Muzi L. Metal-organic frameworks for hepatocellular carcinoma therapy and mechanism. Front Pharmacol,2022,131025780-1025780. [19] 张穹,刘纯,陈明,等. 肝细胞癌TACE术后病灶存活或复发18F-FDG PET/CT和增强CT诊断价值Meta分析.中华肿瘤防治杂志,2021,28(4):302-309. [20] Shalaby S, Burra P, Senzolo M. Hepatic venous pressure gradient in hepaticresection for hepatocellular carcinoma. Hepatoma Res,2023,9:521-528. |